Noema Pharma AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.noemapharma.com
Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
- Conditions
- MenopauseHot FlashesMenopause Syndrome
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Noema Pharma AG
- Target Recruit Count
- 24
- Registration Number
- NCT06385795
- Locations
- 🇺🇸
Noema PMM-201 Site #104, San Diego, California, United States
🇺🇸Noema PMM-201 Site #102, Jacksonville, Florida, United States
🇺🇸Noema PMM-201 Site #101, Atlanta, Georgia, United States
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Noema Pharma AG
- Target Recruit Count
- 180
- Registration Number
- NCT06315751
- Locations
- 🇺🇸
Noema TTS-201 Site #63, Dothan, Alabama, United States
🇺🇸Noema TTS-201 Site #81, Sun City, Arizona, United States
🇺🇸Noema TTS-201 Site #95, Bellflower, California, United States
A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia
- Conditions
- Trigeminal Neuralgia
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Noema Pharma AG
- Target Recruit Count
- 30
- Registration Number
- NCT06019338
- Locations
- 🇺🇸
Kainzen Centre, La Jolla, California, United States
🇬🇧ULC Research, London, United Kingdom
A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Noema Pharma AG
- Target Recruit Count
- 75
- Registration Number
- NCT05583955
- Locations
- 🇦🇺
Noema Investigator site, Sydney, New South Wales, Australia
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
- Conditions
- Trigeminal Neuralgia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Noema Pharma AG
- Target Recruit Count
- 166
- Registration Number
- NCT05217628
- Locations
- 🇺🇸
Kaizen Brain Center (Site #: 1001), La Jolla, California, United States
🇺🇸L & A Morales Healthcare INC (Site#: 1011), Miami, Florida, United States
🇺🇸University of South Florida (Site #: 1002), Tampa, Florida, United States
- Prev
- 1
- 2
- Next